# Therapeutically Targeting Ubiquitin Receptors in Multiple Myeloma

> **NIH NIH P50** · DANA-FARBER CANCER INST · 2022 · $405,145

## Abstract

PROJECT SUMMARY 
The ubiquitin proteasome system (UPS) regulates a non-lysosomal intracellular protein degradation pathway 
that is required for cell-cycle progression, signal transduction, removal of damaged proteins, and maintenance 
of normal protein homeostasis. Dysfunction of the UPS is associated with pathogenesis of various human 
diseases including multiple myeloma (MM); therefore, inhibitors of UPS pathways offer great promise as a 
novel therapeutic strategy. We have characterized targeting of UPS in MM using our in vitro and in vivo models 
of the MM cell in the bone marrow (BM) milieu, specifically delineating the molecular and cellular mechanisms 
whereby proteasome inhibitors target tumor cells, host tumor interactions, and the BM microenvironment to 
overcome drug resistance. These preclinical studies and clinical trials provided the basis for FDA approval of 
proteasome inhibitors (PI) bortezomib, carfilzomib, and ixazomib for the treatment of relapsed/refractory and 
newly diagnosed MM, and importantly, validated the 20S proteasome in the UPS as a therapeutic target in 
MM. Even though these therapies are major advances, they are associated with possible off-target toxicities 
and the eventual development of drug-resistance. Therefore, our more recent studies have focused on 
targeting enzymes modulating protein ubiquitin-conjugation and -deconjugation rather than the proteasome 
itself, with the goal of generating more specific and less toxic anti-tumor agents. In the last grant period, we 
advanced inhibitors targeting deubiquitylating enzymes USP14/UCHL5 from the bench to the bedside and first 
in man clinical trials. Our most recent efforts have focused on targeting another major component of UPS, 
Ubiquitin Receptors (UbRs). Our Preliminary Studies show that UbR Rpn13/ADRM1 is more highly expressed 
in MM cells than in normal plasma cells, and that inhibiting Rpn13 triggers MM cell growth inhibition, even in 
MM PI resistant MM. The current proposal aims to investigate the hypothesis that inhibition of the UPS at the 
level of UbRs, upstream of the proteasome, can inhibit MM cell growth and overcome PI resistance. To 
achieve these goals, we will pursue the following Specific Aims: Specific Aim 1: Functional characterization of 
Ubiquitin Receptors in MM pathogenesis. Specific Aim 2: To design specific UbR inhibitors and/or degraders, 
and assess their in vitro specificity and mechanism of action, either alone or in scientifically-informed 
combinations. Specific Aim 3: To pre-clinically evaluate in vivo anti-MM activity of novel UbR inhibitors and/or 
degraders, either alone or in combination therapies, for translation into clinical trials. This new paradigm to 
target UPS pathways in MM at the level of Ubiquitin Receptors (UbRs) has great promise not only to overcome 
PI resistance and improve patient outcome, but may also serve as a model for targeted therapeutics in other 
cancers.

## Key facts

- **NIH application ID:** 10449084
- **Project number:** 5P50CA100707-19
- **Recipient organization:** DANA-FARBER CANCER INST
- **Principal Investigator:** KENNETH C. ANDERSON
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $405,145
- **Award type:** 5
- **Project period:** 2003-09-16 → 2024-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10449084

## Citation

> US National Institutes of Health, RePORTER application 10449084, Therapeutically Targeting Ubiquitin Receptors in Multiple Myeloma (5P50CA100707-19). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10449084. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*